ストックスクリーナーアプリを入手
44.86
5.43%
2.31
プレマーケット:
44.90
0.04
+0.09%
Enliven Therapeutics Inc (ELVN) 最新ニュース
[144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
What Does Enliven Therapeutics’ Rule 144 Filing Mean For Investors? - Kalkine Media
Enliven Therapeutics closes $460M public offering - Investing.com UK
Enliven Therapeutics Closes Upsized $460 Million Public Offering - marketscreener.com
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire
Responsive Playbooks and the ELVN Inflection - Stock Traders Daily
Enliven Therapeutics reports positive phase 1 CML data and FDA alignment for phase 3 trial (ELVN) - MSN
Enliven Therapeutics Prices $400 Million Public Offering - Moomoo
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating - Moomoo
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial - Insider Monkey
5 Stocks That Absolutely Exploded Higher - Insider Monkey
Why Is Enliven Therapeutics Stock (ELVN) Up Today? - TipRanks
ELVN Stock Jumps As FDA-Cleared Path Fuels Phase 3 Push - timothysykes.com
Enliven Therapeutics Prices ~$376 Million Equity Offering; Jefferies, Goldman, Morgan Stanley Lead - TradingView
Enliven Therapeutics (Nasdaq: ELVN) plans $400M stock and warrant sale - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) raises $376M via 8.93M-share offering - Stock Titan
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Yahoo Finance
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Enliven (ELVN) Sees Significant Price Increase - GuruFocus
ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial - StocksToTrade
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - Kalkine
Enliven Therapeutics (ELVN) Stock Surges On FDA, Trial Wins - timothysykes.com
Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants - MSN
Key facts: Enliven posts ELVN-001 Phase 1 data; files $250M offering - TradingView
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid LeukemiaSlideshow (NASDAQ:ELVN) 2026-06-12 - Seeking Alpha
Enliven Therapeutics prices $400M public offering at $37.50 - Investing.com UK
Enliven Therapeutics prices $400M public offering at $37.50 By Investing.com - Investing.com Canada
Enliven Therapeutics Expects Offering to Close on or About June 15 >ELVN - Moomoo
Biotech Enliven prices ~$400 million stock and warrant sale - Stock Titan
Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per Share - TradingView
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
Enliven Therapeutics launches $250M stock offering - Investing.com UK
Enliven Therapeutics (ELVN) offers $250M stock with pre-funded warrants - Stock Titan
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid - BioWorld News
Enliven Therapeutics launches $250M public stock offering - MSN
Enliven Therapeutics launches $250M stock offering By Investing.com - Investing.com Australia
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
ELVN Stock Pops As Wall Street Targets Phase 3 Catalyst - StocksToTrade
ELVN Stock Jumps As Analysts Hike Price Targets - StocksToTrade
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga
ELVN Stock Pops As Analysts Hike Biotech Price Targets - timothysykes.com
Enliven reports phase 1 trial data for CML drug candidate - Investing.com UK
ELVN: ELVN-001 shows strong efficacy and safety in CML, advancing to pivotal Phase 3 trials - TradingView
Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN) - Yahoo Finance
Why is Enliven Therapeutics stock surging today? By Investing.com - Investing.com Canada
Biggest stock movers: DAN, ORCL, HUMA, and more - Seeking Alpha
Enliven Shares Climb on Positive Leukemia Drug Trial Data - marketscreener.com
Enliven Therapeutics, DXC Technology, Humacyte - TradingView
Enliven Therapeutics stock surges on positive trial data By Investing.com - Investing.com South Africa
Enliven posts new trial data for leukemia drug (ELVN:NASDAQ) - Seeking Alpha
Enliven Therapeutics stock surges on positive trial data - Investing.com UK
ELVN: ELVN-001 shows strong efficacy and safety in CML, advancing to Phase 3 after FDA alignment - TradingView
Enliven Therapeutics reports positive Phase 1 ENABLE data; 80 mg QD set for Phase 3 - TradingView
Enliven (NASDAQ: ELVN) shares updated ELVN-001 CML data and FDA Phase 3 alignment - Stock Titan
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data - TradingView
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components - PR Newswire
Enliven Therapeutics prices $400M public offering of common stock and pre-funded warrants. - Pluang
Enliven Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
Enliven TherapeuticsIncreases Authorized Common Stock To 200 Million Shares Effective June 9, 2026SEC Filing - TradingView
Enliven Therapeutics director Lori Kunkel sells over $345k in shares - Investing.com Nigeria
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):